차세대 약물 접합체 시장 보고서(2026년)

Next-generation drug conjugates are advanced formulations of drug conjugates engineered to boost the efficacy and safety of targeted therapies. They employ cutting-edge targeting technologies and superior payloads to deliver powerful treatments straight to diseased cells with improved precision and fewer side effects.

The primary categories of next-generation drug conjugates include peptide receptor radionuclide therapy, ligand-mediated RNAi conjugates, ligand-conjugated antisense medicines, and peptide drug conjugates. Peptide Receptor Radionuclide Therapy (PRRT) represents a targeted cancer treatment that employs radioactive peptides to attach to and eliminate tumor cells displaying specific receptors. Targeting ligands encompass amino sugars, lipids, peptides, small molecules, and virus-like particles, while payload types consist of oligonucleotides, radionuclides, peptides, and small molecules. This therapy may be delivered as monotherapy or combination therapy for diverse indications, such as gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis from breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, and more.

Tariffs have raised costs for imported cytotoxic payloads, linker technologies, and advanced manufacturing equipment used in the next generation drug conjugates market. These impacts are most significant in North America and Europe, where complex biopharmaceutical production depends on specialized global suppliers. Rising tariff related expenses have increased development and manufacturing costs for antibody drug conjugates and related therapies. This has influenced investment prioritization and capacity planning among biopharmaceutical companies. However, tariffs are also driving localization of high value biopharmaceutical manufacturing, expanded in region capabilities, and stronger control over critical production technologies.

The next generation drug conjugates market research report is one of a series of new reports from The Business Research Company that provides next generation drug conjugates market statistics, including next generation drug conjugates industry global market size, regional shares, competitors with a next generation drug conjugates market share, detailed next generation drug conjugates market segments, market trends and opportunities, and any further data you may need to thrive in the next generation drug conjugates industry. This next generation drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $2.47 billion in 2025 to $2.85 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to limitations of conventional chemotherapy, advancements in biologics research, increased cancer prevalence, growth of specialty pharma companies, clinical success of early drug conjugates.

The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to expansion of personalized medicine, growing oncology drug pipelines, innovation in linker and payload chemistry, rising r&d investments, increasing regulatory approvals. Major trends in the forecast period include rising adoption of targeted drug delivery systems, increasing focus on precision oncology therapies, expansion of advanced payload technologies, growing clinical use of conjugated therapeutics, higher demand for safer high-efficacy drugs.

The increasing incidence of cancer is anticipated to fuel the expansion of the next-generation drug conjugates market in the future. Cancer encompasses a range of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells throughout the body. This surge in cancer cases stems mainly from an aging population, lifestyle choices, environmental influences, better diagnostic methods, genetic predispositions, and infectious causes. Next-generation drug conjugates address cancer by transporting targeted treatments straight to tumor cells, boosting therapeutic effectiveness and reducing harm to normal tissues. For instance, in February 2025, Cancer Australia-a government agency in Australia-reported 4,641 new pancreatic cancer diagnoses in 2024, including 2,414 in males and 2,227 in females, up from 3,968 cases the previous year. Thus, the growing burden of cancer is propelling the next-generation drug conjugates market forward.

Major companies in the next-generation drug conjugates market are pursuing strategic partnerships to boost their research and development capabilities, speed up product innovation, and grow their market presence. Strategic partnerships involve companies combining their strengths and resources to gain mutual benefits and achieve success. For example, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, collaborated with AbCellera Biologics Inc., a Canada-based biotechnology company, to create first-in-class precision antibody-drug conjugates (ADCs) for oncology. The collaboration focuses on discovering, developing, and commercializing novel antibody-drug conjugates (ADCs), beginning with a program that pairs a SMARCA degrader with a novel antibody. This approach seeks to extend the therapeutic potential of Prelude's small-molecule SMARCA2 selective degraders to a larger patient population, particularly those with cancers not linked to SMARCA4 mutations.

In March 2024, Johnson & Johnson-a U.S.-based producer of pharmaceuticals and medical devices-purchased Ambrx Biopharma for $2 billion. This acquisition seeks to bolster Johnson & Johnson's oncology offerings and accelerate progress on next-generation antibody drug conjugates designed to revolutionize cancer care. Ambrx Biopharma, a U.S.-based clinical-stage biopharmaceutical firm, specializes in next-generation drug conjugates.

Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

North America was the largest region in the next generation drug conjugates market in 2025. The regions covered in the next generation drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the next generation drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation drug conjugates market consists of revenues earned by entities by providing services such as targeted cancer therapies, gene therapy conjugates, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation drug conjugates market also includes sales of small molecule drug conjugates, RNA-targeted conjugates, and enzyme-linked drug conjugates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Drug Conjugates Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses next generation drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next generation drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy; Ligand Mediated RNAI Conjugate; Ligand Conjugated Anti Sense Medicine; Peptide Drug Conjugate
• 2) By Targeting Ligand Type: Amino Sugar; Lipid; Peptide; Small Molecule; Virus-Like Particles
• 3) By Payload Type: Oligonucleotide; Radionuclide; Peptide; Small Molecule
• 4) By Therapy: Monotherapy; Combination Therapy
• 5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors; Prostate Cancer; Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases; Hereditary Transthyretin Amyloidosis; Atherosclerotic Cardiovascular Diseases; Severe Hypertriglyceridemia; Hereditary Angioedema; Acute Hepatic Porphyria; Other Indications
• Subsegments:
• 1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues; Radiolabeled Peptides
• 2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates; ShRNA Ligand Conjugates
• 3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates; Antisense Oligonucleotide Ligand Conjugates
• 4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates; Therapeutic Peptide Conjugates
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis International AG; AstraZeneca PLC; Daiichi Sankyo Company Limited; Eisai Co Ltd.; Bicycle Therapeutics plc; Zymeworks Inc.; Genentech Inc.; MacroGenics Inc.; Abzena plc; Innate Pharma S.A.; CytomX Therapeutics Inc.; ImmunoGen Inc.; Ascentage Pharma Group International; Mersana Therapeutics Inc.; Antengene Corporation Limited; Nurix Therapeutics Inc.; Tubulis GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Next Generation Drug Conjugates Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Next Generation Drug Conjugates Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Next Generation Drug Conjugates Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Next Generation Drug Conjugates Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Drug Delivery Systems
  • 4.2.2 Increasing Focus On Precision Oncology Therapies
  • 4.2.3 Expansion Of Advanced Payload Technologies
  • 4.2.4 Growing Clinical Use Of Conjugated Therapeutics
  • 4.2.5 Higher Demand For Safer High-Efficacy Drugs

5. Next Generation Drug Conjugates Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Centers
• 5.3 Specialty Clinics
• 5.4 Biopharmaceutical Companies
• 5.5 Research Organizations

6. Next Generation Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Next Generation Drug Conjugates Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Next Generation Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Next Generation Drug Conjugates Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Next Generation Drug Conjugates Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Next Generation Drug Conjugates Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Next Generation Drug Conjugates Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Next Generation Drug Conjugates Market Segmentation

• 9.1. Global Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
• 9.2. Global Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
• 9.3. Global Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oligonucleotide, Radionuclide, Peptide, Small Molecule
• 9.4. Global Next Generation Drug Conjugates Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monotherapy, Combination Therapy
• 9.5. Global Next Generation Drug Conjugates Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
• 9.6. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Receptor Radionuclide Therapy (PRRT), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Somatostatin Analogues, Radiolabeled Peptides
• 9.7. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Mediated RNAi Conjugate, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
• 9.8. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Conjugated Anti-Sense Medicine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
• 9.9. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Drug Conjugate, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates

10. Next Generation Drug Conjugates Market Regional And Country Analysis

• 10.1. Global Next Generation Drug Conjugates Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Next Generation Drug Conjugates Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Next Generation Drug Conjugates Market

• 11.1. Asia-Pacific Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Next Generation Drug Conjugates Market

• 12.1. China Next Generation Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Next Generation Drug Conjugates Market

• 13.1. India Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Next Generation Drug Conjugates Market

• 14.1. Japan Next Generation Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Next Generation Drug Conjugates Market

• 15.1. Australia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Next Generation Drug Conjugates Market

• 16.1. Indonesia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Next Generation Drug Conjugates Market

• 17.1. South Korea Next Generation Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Next Generation Drug Conjugates Market

• 18.1. Taiwan Next Generation Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Next Generation Drug Conjugates Market

• 19.1. South East Asia Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Next Generation Drug Conjugates Market

• 20.1. Western Europe Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Next Generation Drug Conjugates Market

• 21.1. UK Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Next Generation Drug Conjugates Market

• 22.1. Germany Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Next Generation Drug Conjugates Market

• 23.1. France Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Next Generation Drug Conjugates Market

• 24.1. Italy Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Next Generation Drug Conjugates Market

• 25.1. Spain Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Next Generation Drug Conjugates Market

• 26.1. Eastern Europe Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Next Generation Drug Conjugates Market

• 27.1. Russia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Next Generation Drug Conjugates Market

• 28.1. North America Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Next Generation Drug Conjugates Market

• 29.1. USA Next Generation Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Next Generation Drug Conjugates Market

• 30.1. Canada Next Generation Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Next Generation Drug Conjugates Market

• 31.1. South America Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Next Generation Drug Conjugates Market

• 32.1. Brazil Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Next Generation Drug Conjugates Market

• 33.1. Middle East Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Next Generation Drug Conjugates Market

• 34.1. Africa Next Generation Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Segmentation By Targeting Ligand Type, Segmentation By Payload Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Next Generation Drug Conjugates Market Regulatory and Investment Landscape

36. Next Generation Drug Conjugates Market Competitive Landscape And Company Profiles

• 36.1. Next Generation Drug Conjugates Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Next Generation Drug Conjugates Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Next Generation Drug Conjugates Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

37. Next Generation Drug Conjugates Market Other Major And Innovative Companies

• AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc.

38. Global Next Generation Drug Conjugates Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Next Generation Drug Conjugates Market

40. Next Generation Drug Conjugates Market High Potential Countries, Segments and Strategies

• 40.1 Next Generation Drug Conjugates Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Next Generation Drug Conjugates Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Next Generation Drug Conjugates Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer